What is Perspective Therapeutics's G&A?

Perspective Therapeutics (CATX) reported G&A of $6.99M in Q1 2026.

How has Perspective Therapeutics's G&A changed year-over-year?

Perspective Therapeutics's G&A decreased by 10.9% year-over-year, from $7.84M to $6.99M.

What is the long-term trend for Perspective Therapeutics's G&A?

Over 4 years (2021 to 2025), Perspective Therapeutics's G&A has grown at a 59.3% compound annual growth rate (CAGR), from $4.69M to $30.23M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Perspective Therapeutics CATX G&A

G&A at other companies

CytomX TherapeuticsCTMX

$10.69M+13.4%

Monopar TherapeuticsMNPR

$1.74M+10.1%

ImmunomeIMNM

$12.95M+21.1%

Lantheus HoldingsLNTH

$57.53M+1.3%

ZymeworksZYME

$15.07M-11.3%

Spyre Therapeutics, Inc.SYRE

$15.23M+27.5%

Other financials

Income statement

See full

Revenue$2.2M+27.3%

Gross profit$738.0K+78.3%

Operating income-$28.3M-29.5%

Net income-$26.2M-44.1%

EPS (diluted)-$0.250.0%

Balance sheet

See full

Cash & equivalents$54.0M+21.5%

Total debt$4.2M+10.9%

Total equity$347.4M+22.1%

Total assets$410.8M+24.7%

Cash flow

See full

Operating cash flow-$31.5M-45.8%

CapEx$6.9M+47.3%

Free cash flow-$38.3M-46.1%

Valuation

See full

Market cap$342.14M+33.2%

Enterprise value$292.34M+35.2%

P/S34.2×+19.6×

Profitability

See full

Gross margin33.1%-7.1pp

Operating margin-292.7%-553pp

Net margin-218.4%-781pp

FCF margin-1,073.3%—

Returns & leverage

See full

Return on equity-35.2%+2.3pp

Debt / equity0×0.0×

Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Perspective Therapeutics's G&A?: Perspective Therapeutics (CATX) reported G&A of $6.99M in Q1 2026.
How has Perspective Therapeutics's G&A changed year-over-year?: Perspective Therapeutics's G&A decreased by 10.9% year-over-year, from $7.84M to $6.99M.
What is the long-term trend for Perspective Therapeutics's G&A?: Over 4 years (2021 to 2025), Perspective Therapeutics's G&A has grown at a 59.3% compound annual growth rate (CAGR), from $4.69M to $30.23M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.